SEATTLE, WA — June 24, 2002 — The anti-epileptic drug topiramate (Topamax) provides substantial migraine relief for patients ages 8-10, investigators from Pediatric Epilepsy and Neurology Specialists of Tampa, Fla. reported at the annual meeting of the American Headache Society.
“Topiramate therapy was associated with a substantial reduction in migraine headache frequency and severity, and reduced the degree of associated disability,” the researchers wrote.
The research team performed a chart review of pediatric and adolescent patients who had been under care at their clinic for migraine and migraine-like headaches and who had been treated with topiramate. They assessed frequency, severity and disability associated with migraine before and after treatment.
They studied the patient charts for comorbid conditions, body weight, adverse events and use of other drugs during treatment. The investigators identified 10 male and 24 female adolescents, mean age 14 years, who were diagnosed with migraines (16), chronic daily headaches (17) and headaches associated with hydrocephalus (1). The mean dosage for topiramate given to the subjects was between 138 +/- 85 mg (range 15-325 mg).
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!